Literature DB >> 15206667

Dose response and dose equivalence of antipsychotics.

John M Davis1, Nancy Chen.   

Abstract

We review evidence from randomized, placebo-controlled studies of patients with schizophrenia or schizoaffective disorder, which compared 2 or more doses of an antipsychotic to calculate the dose-response curve for each first-generation (typical) antipsychotic (FGA) or second-generation (atypical) antipsychotic (SGA) and as a group (based on dose equivalence). We identified the near-maximal effective dose (ED; ie, the threshold dose necessary to produce all or almost all the clinical responses for each drug). In randomized, fixed-dose studies of SGAs, the near-maximal efficacy dose for olanzapine may be greater than 16 mg; for risperidone, it is 4 mg; and for ziprasidone, it is 120 mg. Risperidone at 2 mg daily is 50% less efficacious than higher doses. Olanzapine at about 6 mg is approximately 33% less effective than higher doses. Aripiprazole at 10 mg daily was fully efficacious. Doses of clozapine well above 400 mg are necessary for optimal treatment of many schizophrenia patients. We found 3.3 to 10 mg haloperidol to be the near-maximal ED range. We find no evidence that doses higher than these are more effective. We failed to find that high doses of haloperidol (or all other first-generation comparison drugs converted to equivalent doses) were less effective than medium doses (3.3 to 10 mg). While high-dose FGAs are not less effective, we feel it is important not to avoid using high dose to avoid excessive toxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15206667     DOI: 10.1097/01.jcp.0000117422.05703.ae

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  75 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.

Authors:  Robert C Smith; Stefan Leucht; John M Davis
Journal:  Psychopharmacology (Berl)       Date:  2018-11-30       Impact factor: 4.530

3.  Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia.

Authors:  Stephen J Glatt; Ian P Everall; William S Kremen; Jacques Corbeil; Roman Sásik; Negar Khanlou; Mark Han; Choong-Chin Liew; Ming T Tsuang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-13       Impact factor: 11.205

4.  Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features.

Authors:  Jonathan Rabinowitz; Stephen Z Levine; Orna Barkai; Ori Davidov
Journal:  Schizophr Bull       Date:  2008-02-26       Impact factor: 9.306

5.  Sleep and Parasympathetic Activity During Rest and Stress in Healthy Adolescents and Adolescents With Bipolar Disorder.

Authors:  Melynda D Casement; Tina R Goldstein; John Merranko; Sarah M Gratzmiller; Peter L Franzen
Journal:  Psychosom Med       Date:  2019 Nov/Dec       Impact factor: 4.312

6.  Modality-specific alterations in the perception of emotional stimuli in Bipolar Disorder compared to Healthy Controls and Major Depressive Disorder.

Authors:  Aaron C Vederman; Sara L Weisenbach; Lisa J Rapport; Hadia M Leon; Brennan D Haase; Lindsay M Franti; Michael-Paul Schallmo; Erika F H Saunders; Masoud M Kamali; Jon-Kar Zubieta; Scott A Langenecker; Melvin G McInnis
Journal:  Cortex       Date:  2011-05-11       Impact factor: 4.027

Review 7.  Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose.

Authors:  Richard A Hansen; Charity G Moore; Stacie B Dusetzina; Brian I Leinwand; Gerald Gartlehner; Bradley N Gaynes
Journal:  Med Decis Making       Date:  2009-01-13       Impact factor: 2.583

8.  Equivalent linear change in cognition between individuals with bipolar disorder and healthy controls over 5 years.

Authors:  Kelly A Ryan; Shervin Assari; Kaley Angers; David F Marshall; Kristin Hinrichs; Rebecca Easter; Pallavi Babu; Bethany D Pester; Scott A Langenecker; Melvin G McInnis
Journal:  Bipolar Disord       Date:  2017-09-14       Impact factor: 6.744

9.  Differentiating unipolar and bipolar depression by alterations in large-scale brain networks.

Authors:  Roberto Goya-Maldonado; Katja Brodmann; Maria Keil; Sarah Trost; Peter Dechent; Oliver Gruber
Journal:  Hum Brain Mapp       Date:  2015-11-27       Impact factor: 5.038

10.  No evidence of an association between A218C polymorphism of the tryptophan hydroxylase 1 gene and aggression in schizophrenia in a Korean population.

Authors:  Youl-Ri Kim; Joo Young Lee; Sung Kil Min
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.